ATE499102T1 - Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen - Google Patents

Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen

Info

Publication number
ATE499102T1
ATE499102T1 AT07759007T AT07759007T ATE499102T1 AT E499102 T1 ATE499102 T1 AT E499102T1 AT 07759007 T AT07759007 T AT 07759007T AT 07759007 T AT07759007 T AT 07759007T AT E499102 T1 ATE499102 T1 AT E499102T1
Authority
AT
Austria
Prior art keywords
cell proliferation
proliferation disorders
pyrimidinediamine compounds
treating cell
cell proliferative
Prior art date
Application number
AT07759007T
Other languages
German (de)
English (en)
Inventor
Esteban Masuda
Donald Payan
Elliott Grossbard
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE499102T1 publication Critical patent/ATE499102T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT07759007T 2006-04-18 2007-03-21 Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen ATE499102T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/407,233 US8227455B2 (en) 2005-04-18 2006-04-18 Methods of treating cell proliferative disorders
PCT/US2007/064511 WO2007124221A1 (en) 2006-04-18 2007-03-21 Methods of treating cell proliferative disorders by using pyrimidinediamine compounds

Publications (1)

Publication Number Publication Date
ATE499102T1 true ATE499102T1 (de) 2011-03-15

Family

ID=38477280

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07759007T ATE499102T1 (de) 2006-04-18 2007-03-21 Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen

Country Status (10)

Country Link
US (2) US8227455B2 (enExample)
EP (1) EP2010181B1 (enExample)
JP (1) JP5204761B2 (enExample)
AT (1) ATE499102T1 (enExample)
CA (1) CA2649549C (enExample)
DE (1) DE602007012677D1 (enExample)
DK (1) DK2010181T3 (enExample)
ES (1) ES2364657T3 (enExample)
SI (1) SI2010181T1 (enExample)
WO (1) WO2007124221A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1663242T3 (da) * 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US20090048214A1 (en) * 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
WO2009003136A1 (en) * 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
US20090088371A1 (en) * 2007-08-28 2009-04-02 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
WO2009061909A2 (en) * 2007-11-07 2009-05-14 Rigel Pharmaceuticals, Inc. Wet granulation using a water sequestering agent
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
PL2305300T3 (pl) 2008-07-10 2016-09-30 Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi
CN102292333B (zh) 2009-01-15 2015-05-13 里格尔药品股份有限公司 蛋白激酶c抑制剂及其用途
EP2501705B1 (en) 2009-11-20 2014-08-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
JP6067550B2 (ja) 2010-04-13 2017-01-25 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
JP5744021B2 (ja) 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
MX2013010898A (es) 2011-03-24 2013-12-06 Chemilia Ab Novedoso derivados de la pirimidina.
WO2012167423A1 (en) 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
SMT201900071T1 (it) 2011-07-28 2019-02-28 Rigel Pharmaceuticals Inc Nuove formulazioni di (trimetossifenilammino)pirimidinile
DK2799431T3 (en) 2011-12-28 2018-03-26 Fujifilm Corp Hitherto unknown nicotinamide derivatives or salts thereof
UY34807A (es) 2012-05-16 2013-12-31 Novartis Ag Derivados monocíclicos de heteroarilcicloalquil- diamina
WO2013189241A1 (zh) * 2012-06-20 2013-12-27 上海恒瑞医药有限公司 嘧啶二胺类衍生物、其制备方法及其在医药上的应用
CN103804382A (zh) * 2012-11-05 2014-05-21 韩文毅 一类治疗湿疹的化合物及其用途
CN103102412B (zh) * 2013-01-29 2014-03-26 陈仁杰 人源抗鼻咽癌LMP2A胞外区抗体Fab及其应用
EP3247375B1 (en) * 2015-01-23 2021-08-04 Erasmus University Medical Center Rotterdam Anti-senescence compounds and uses thereof
ES2913119T3 (es) * 2015-08-12 2022-05-31 Portola Pharm Inc Cerdulatinib para tratar mieloma
RS65069B1 (sr) * 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
RU2621187C1 (ru) * 2016-05-13 2017-06-01 Общество с ограниченной ответственностью "Молекулярные Технологии" Новая кристаллическая солевая форма 2,2-диметил-6-((4-((3,4,5-триметоксифенил)амино)-1,3,5-триазин-2-ил)амино)-2н-пиридо[3,2-в][1,4]оксазин-3(4н)-она для медицинского применения
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
EP3512519A1 (en) 2016-09-14 2019-07-24 Gilead Sciences, Inc. Syk inhibitors
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
JPWO2023182460A1 (enExample) * 2022-03-24 2023-09-28
WO2024037910A1 (en) * 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Syk inhibitors for use in the treatment of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
AU754965B2 (en) * 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
WO2003026665A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
WO2003040141A1 (en) 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
WO2003055489A1 (en) 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
GEP20074230B (en) * 2002-03-20 2007-11-12 Bristol Myers Squibb Co Phosphate prodrugs of fluorooxindoles
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
WO2004014832A2 (en) 2002-08-02 2004-02-19 Vanetta S.P.A. Redox process particularly for the production of menadione and use of polyoxometalates
JP2006524688A (ja) 2003-03-25 2006-11-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
DK1663242T3 (da) 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
WO2005027848A2 (en) 2003-09-19 2005-03-31 Barnes-Jewish Hospital Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
WO2005048953A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
US20090048214A1 (en) 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds

Also Published As

Publication number Publication date
US8481521B2 (en) 2013-07-09
WO2007124221A1 (en) 2007-11-01
DK2010181T3 (da) 2011-06-14
ES2364657T3 (es) 2011-09-08
US8227455B2 (en) 2012-07-24
EP2010181A1 (en) 2009-01-07
CA2649549A1 (en) 2007-11-01
SI2010181T1 (sl) 2011-06-30
JP5204761B2 (ja) 2013-06-05
DE602007012677D1 (de) 2011-04-07
JP2009534397A (ja) 2009-09-24
CA2649549C (en) 2011-10-18
EP2010181B1 (en) 2011-02-23
US20060276459A1 (en) 2006-12-07
US20120245127A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
DE602007012677D1 (de) Verfahren zur behandlung von zellproliferationsstörungen mit pyrimidindiaminverbindungen
EA201590230A1 (ru) Соединения пиразолопиримидина в качестве ингибиторов киназ
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
ATE438650T2 (de) Proteasominhibitoren und verfahren zu deren anwendung
EA201490814A1 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
PH12014501355B1 (en) Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors
IL178675A0 (en) Monocyclic heterocycles as kinase inhibitors
PH12015500181A1 (en) Atx modulating agents
IL184678A0 (en) Proteasome inhibitors and methods of using the same
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
EA201401062A1 (ru) Бициклические пиразиноновые производные
DK1896421T3 (da) Benzocyclohetapyridiner som hæmmere af receptoren tyrosinkinase MET
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
MX2012010212A (es) Terapias inhibidoras de autofagia basadas en tioxantona para tratar el cancer.
MY162518A (en) Proteasome inhibitors and methods of using the same
NO20080417L (no) Benzosykloheptapyridiner som inhibitorer av reseptortyrosinkinasen MET
EA201791179A1 (ru) Дейтерированный триазолопиридазин в качестве модулятора киназы
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
ATE426605T1 (de) Inhibitoren von mitotischem kinesin
ATE482218T1 (de) Inhibitoren von mitotischem kinesin
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
TW200602023A (en) Monocyclic heterocycles as kinase inhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties